“Magic” Mushroom Compound Eases Depression

Psilocybin led to an improvement in symptoms for treatment-resistant patients, according to a small study.

Written byTanya Lewis
| 2 min read

Register for free to listen to this article
Listen with Speechify
0:00
2:00
Share

Magic mushrooms (Psilocybe semilanceata)WIKIMEDIA, SCIENCEMAN71So-called magic mushrooms may have medicinal uses. Researchers at Imperial College London gave psilocybin, the active ingredient in the hallucinogenic fungi, to 12 people with treatment-resistant depression. All 12 patients saw improvement in their symptoms, and five of them were still in complete remission three months after treatment, according to a study published today (May 17) in The Lancet Psychiatry.

“That is pretty remarkable in the context of currently available treatments,” study coauthor Robin Carhart-Harris of Imperial College told Nature News. “We can give psilocybin to depressed patients, they can tolerate it, and it is safe. This gives us an initial impression of the effectiveness of the treatment.”

Carhart-Harris and colleagues gave six men and six women with unipolar treatment-resistant major depression two oral doses of psilocybin (one low-dose and one high-dose) seven days apart, in a “supportive setting.” The patients provided self-reports on the intensity of the drug’s effects, and were monitored for negative reactions. The researchers assessed depressive symptoms one week to three months after the end of treatment.

None of the patients reported experiencing serious adverse outcomes. Some said they experienced side ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Related Topics

Meet the Author

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies